Miscarriage Management (threatened/incomplete/missed)
Clinical detail
Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.
Confirm pregnancy location and diagnostic certainty before treatment. Discuss expectant, medical and surgical options alongside bleeding risk, infection, previous experiences and the patient’s preferences.
Assessment & interpretation
- Borderline ultrasound findings need the recommended repeat-scan interval or a second opinion; do not diagnose pregnancy failure from menstrual dates alone.
- Assess bleeding, pain, infection and emotional support needs before deciding whether outpatient care is appropriate.
Decisions that change management
- NICE uses 7–14 days of expectant care as the first option when suitable. Infection, increased haemorrhage risk or unacceptable waiting favour another route.
- For missed miscarriage: mifepristone 200 mg orally once, followed 48 hours later by misoprostol 800 micrograms vaginally, orally or sublingually, unless the sac has already passed.
- For incomplete miscarriage: misoprostol 600 micrograms vaginally, orally or sublingually once; 800 micrograms is an alternative. Do not add mifepristone for incomplete miscarriage.
Follow-up & safety-netting
- Supply a urine pregnancy test for 3 weeks after medical management; review a positive result for retained, ectopic or molar pregnancy.
- Persistent heavy bleeding, fever or pelvic pain still needs assessment even with a negative test. Contact the service if bleeding has not begun within 48 hours of misoprostol.
Admission & discharge
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Admit heavy ongoing bleeding/instability, suspected sepsis, severe uncontrolled pain or inability to complete safe outpatient care. Exclude ectopic pregnancy when the location/outcome is uncertain.
When clinic, day care or home care may be suitable
- Confirmed uncomplicated miscarriage can be managed expectantly, medically or by day-case surgery according to clinical suitability and patient preference.
Before going home
- Bleeding/pain and observations support home care; the diagnosis, chosen approach and possibility of incomplete treatment have been explained.
- After evacuation/anaesthesia, recovery and postoperative assessment are satisfactory, with transport/adult support when needed.
Discharge medicines and treatment changes
- Use only the regimen for the diagnosed type of miscarriage; provide analgesia and antiemetic treatment when needed. Review RhD care using the current applicable pathway.
Medicine doses — use only when indicated
Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.
Pain relief when suitable; provide the selected miscarriage regimen in the treatment section.
- Indication: Short-term maternal postoperative/postpartum pain or other mild pain after assessment; adult ≥50 kg
- MSF oral monograph: no pregnancy or breastfeeding contraindication. The dose does not replace assessment of the cause of pain.
- Pain and functional recovery; investigate increasing pain, fever or other warning symptoms.
- Check all prescribed/OTC paracetamol, weight and hepatic risk; suspected excess dosing requires urgent assessment.
Tests, pending results and their reviewer
- NICE: after expectant management, review completion at 7–14 days; if symptoms resolve, provide a urine pregnancy test for 3 weeks.
- After medical management, urine pregnancy test at 3 weeks; a positive result or persistent bleeding, pain or fever needs assessment even when a test is negative.
Home care and counselling
- Explain expected bleeding/tissue passage, pain relief, hygiene and how to contact the early-pregnancy service. Offer grief support and contraception/future pregnancy advice.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
If bleeding has not begun within 48 hours of misoprostol | Contact the treating service for review rather than repeating treatment independently. |
3 weeks after treatment | Check the home pregnancy test and symptoms; arrange review for a positive result or ongoing concerns. |
Return urgently
- Very heavy bleeding, fainting, severe/worsening pain, fever or offensive discharge needs urgent care.
Treatment
① Immediate stabilization — first minutes
- Resuscitate if shocked; IV access; crossmatch
- Antibiotics FIRST if septic: e.g., ceftriaxone 1 g IV + metronidazole 500 mg IV (or ampicillin-gentamicin-metronidazole triple) then evacuate promptly
③ First-line treatment & drug regimens
| Route | Regimen (incomplete/missed) | Notes |
|---|---|---|
Expectant | Wait 7–14 days; success ~50–80% depending on type | Requires reliable return precautions |
Medical (preferred pharmacologic) | NICE incomplete miscarriage: misoprostol 600 micrograms vaginally, orally or sublingually once (800 micrograms is an alternative); no mifepristone; missed: NICE: mifepristone 200 mg orally once, then 48 hours later misoprostol 800 micrograms vaginally, orally or sublingually once, unless the sac has passed | Analgesia NSAIDs; antiemetics; success ~85–90% missed with combined regimen |
Surgical | Manual vacuum aspiration (MVA) local anaesthesia OR electric VA/S&C under sedation | Immediate definitive; tissue sent histology (exclude molar) |
- NICE NG126 medical management of confirmed missed miscarriage
- Bleeding, pain, fever and haemodynamic symptoms; home urine pregnancy test at 3 weeks with assessment if positive or symptomatic
- NICE NG126 medical management of confirmed incomplete miscarriage
- Bleeding/pain, fever and urine pregnancy test at 3 weeks; positive test or concerning symptoms requires reassessment
④ Drug treatment detail (1 agents)
- Indication: Confirmed missed miscarriage choosing NICE medical management
- Symptoms, bleeding and subsequent completion assessment
Definitive treatment
Complete evacuation (by whichever route) resolves bleeding/infection risk; histopathology of products where molar suspected or recurrent loss.
Monitoring
- Bleeding should reduce within days
- hCG check 1–2 wks (or urine test 3 wks) to confirm resolution
- Temperature/odour surveillance (retained tissue sepsis)
Treatment failure
- Medical failure/retention → offer repeat dose or MVA
- Ongoing heavy bleeding → examine + evacuate
Procedure / surgery
See procedure page: MVA technique (linked).
Escalation
- Septic miscarriage = obstetric emergency: broad-spectrum IV antibiotics + source control (evacuation) ± ICU per sepsis module
⑮ Complications & their management
Haemorrhage
Evacuate; uterotonics; balloon rarely needed
Infection/sepsis
Cultures + IV antibiotics + prompt evacuation; never leave infected tissue
Asherman (late)
Gentle technique reduces risk; amenorrhoea post-EVAC → hysteroscopy referral
Post-treatment care
- Apply the gestation-specific NICE NG126 (June 2026) anti-D criteria, confirming local applicability; do not use a blanket all-loss prophylaxis rule
- Contraception started same-day counselling (ovulation ~2 wks later!)
- Psychological bereavement support; pregnancy-loss information leaflet
- Recurrent loss → dedicated clinic pathway
Diagnosis & assessment
- Heavy bleeding soaking >1 pad/hour
- Fever/rigors/foul discharge (septic abortion → antibiotics THEN evacuation urgently)
- Haemodynamic instability
- Suspected molar (grape-like vesicles/US snowstorm — see molar module)
Definition: Pregnancy loss <24 wks (WHO/RCOG usage; India MTP framework covers termination contexts separately). Threatened = bleeding with closed os + viable pregnancy; Inevitable = open os; Incomplete = partial expulsion; Missed = non-viable retained; Septic = infection overlay.
Initial assessment
- TVS: for CRL ≥7 mm without heartbeat or mean sac diameter ≥25 mm without fetal pole, obtain a second opinion and/or repeat TVS after at least 7 days before diagnosing miscarriage; apply the full NICE repeat-scan criteria
- CBC, group&save, Rh
- Sepsis screen if symptomatic
- Exclude ectopic in all PUL-adjacent presentations
Investigations
| Test | Looking for |
|---|---|
TVS | Viability + completeness |
CBC + Rh | Anaemia/transfusion thresholds; anti-D need |
hCG follow-up where retention uncertain | Decline pattern |
Principles & follow-up
Management principles
Sources (10)
17 April 2019 · updated 17 June 2026 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for miscarriage-management. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Also checked the missed/…
17 April 2019 · updated 17 June 2026 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for pul. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Also checked ultrasound repeat-scan/second-…
2019-04-17 · updated 2026-06-17 · checked 2026-10-18 · verified-live
Open source ↗
Recommendations 1.18.1–1.18.5: no routine anti-D up to 11+6 weeks; offer to RhD-negative patients having medical or surgical management at 12+0–12+6 weeks, consider for heavy/recurrent threatened bleeding at that gestation. Corrected blanket all-loss anti-D wording; applicability to local Indian pol…
· checked 2026-10-18 · verified-live
Open source ↗
Primary public information read: expected recovery, bleeding/pain, infection or continuing-pregnancy concerns, follow-up access and contraceptive counselling; used with WHO abortion guidance, without inventing a mandatory visit after every uncomplicated abortion.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary oral monograph read: adult 1 g 3–4 times daily, maximum 4 g/day, ≥50 kg adult table, 500 mg tablets, duration according to response, hepatic caution and pregnancy/breastfeeding. Pain chapter also checked for 6–8-hour interval. Smaller adults require an individual weight-based prescripti…
· checked 2026-10-18 · verified-live
Open source ↗
Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.
· checked 2026-10-18 · verified-live
Open source ↗
Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.
· checked 2026-10-18 · verified-live
Open source ↗
Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.